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ABSTRACT
Genital Chlamydia trachomatis infection is the leading cause of bacterial sexually transmitted disease in
industrialised countries, particularly among young people. The consequences of chlamydial infection
may involve urethritis, cervicitis, pelvic inflammatory disease, ectopic pregnancy, tubal factor infertility,
epididymitis and prostatitis. In addition, chlamydial infection increases the risk of acquisition of human
immunodeficiency virus and has been associated with cervical cancer. Although screening programmes
exist in a number of countries, the continuously increasing prevalence of chlamydial infections
demonstrates the necessity for health authorities to establish effective screening policies, and the
importance of defining a comprehensive European screening policy is emerging.
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Genital chlamydial infection is the leading cause
of bacterial sexually transmitted disease (STD) in
industrialised countries. The prevalence of lower
genital tract infection with Chlamydia trachomatis
is 2–25%, and is highest in young people [1].
Since 50–70% of genital infections are asympto-
matic [2], and it is estimated that < 10% of
prevalent infections are diagnosed [3], the mor-
bidity and sequelae of the disease impact dra-
matically on the health of women. In the USA,
there are an estimated 4 million new cases
annually, and 50 000 women annually become
infertile as a result of infection [2]. The WHO has
estimated that there were 89 million new cases of
genital chlamydial infections worldwide in 1995
[2] and 92 million in 1999 [4]. In England, the
national screening pilot found that 13.8% of those
aged < 16 years, 10.5% of those aged 16–19 years
and 7.2% of those aged 20–24 years were infected,
with > 60 000 cases reported from genitourinary
medicine clinics in 2000 [3]. In Denmark, almost
13 000 infections were diagnosed in 1998 (75%
among females), corresponding to a prevalence of
4.5% [5]. In Greece, the prevalence of the disease
among women aged 18–35 years has been esti-
mated at 7–10.6% [6,7]. According to the WHO,
chlamydial prevalence rates among pregnant
women in the 1990s were 2.7% in Italy, 3.9% in
France, 4.9% in The Netherlands, 5.4% in
Hungary, 6.2% in the UK, 6.7% in Denmark
and 8% in Iceland [4].
In women, chlamydial infection can cause
urethritis, cervicitis, pelvic inflammatory disease
and, at a later stage, chronic pelvic pain, ectopic
pregnancy and tubal factor infertility. Anti-chla-
mydial antibodies have been documented in
81.5% of infertile women with damaged fallopian
tubes, and in 43.5% of infertile women with
normal tubes [8]. Furthermore, when giving birth,
an infected woman can pass the infection on to
her child, who can develop neonatal conjunctivitis
or pneumonia as a result. In men, chlamydial
infection can cause urethritis, epididymitis and,
probably, prostatitis and infertility. In both sexes,
it can cause mucosal inflammation of the throat
and rectum.
Individuals with bacterial STDs, including chl-
amydial infection, are also at increased risk of
acquiring human immunodeficiency virus.
Strengthening the control of STDs through edu-
cation and access to diagnosis and treatment has
been reported to result in a 42% reduction in the
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incidence of human immunodeficiency virus
infection over a 2-year period [2]. Current data
[9–11] also indicate that cervical cancer is associ-
ated with infection with STD agents other than
oncogenic human papillomavirus. C. trachomatis
infection may induce chronic inflammation, epi-
thelial damage, cytologic cervical atypia and
cervical metaplasia, which in turn may increase
the risk of cervical neoplasia. Serum chlamydial
antibodies have been associated with a 1.8-fold
increased risk of invasive squamous cervical
cancer [11].
Enzyme immunoassay is the diagnostic method
used most commonly, but has a lower detection
limit of 10 000 elementary bodies, and thus lacks
the sensitivity required for screening applications.
Nucleic acid-based amplification tests using PCR,
ligase chain reaction or transcription-mediated
amplification technology have a detection limit of
1–10 elementary bodies and a specificity compar-
able to that of culture. The improved sensitivity of
these assays allows the use of non-invasive spec-
imens, such as first-catch urine specimens, which
are more acceptable to patients. PCR tests using
first-catch urine specimens have been shown to
have sensitivities of 87–97% for men and 82–93%
for women, with specificities of 98–100% for both
genders [2]. They also offer all the advantages of
non-culture tests in terms of specimen transport,
batching, rapid processing time and automation.
The high sensitivity and specificity of nucleic acid-
based amplification tests, combined with the ease
of collection and transport of urine specimens,
makes screening feasible in an outpatient setting
and cost-effective among populations with a
Chlamydia prevalence as low as 3.2%. Pooling of
urine specimens may reduce costs further without
influencing sensitivity [2].
As most infected individuals are asymptomatic
and act as a reservoir that maintains the preval-
ence of the infection, population screening is the
only way to eliminate transmission of Chlamydia.
Universal screening offers the potential to identify
and treat as many infections as possible, thus
decreasing the incidence of future illness and the
economic consequences of sequelae, but is not as
cost-effective as selective screening programmes.
Such selective programmes target the portion of
the population at highest risk and identify most
chlamydial infections without testing all women.
Selective screening programmes are therefore
used more commonly, and most recommend
active screening of women aged < 25 years, as is
recommended in the USA [12], Sweden [1] and
England [13,14].
In 1996, the CDC provided $12.9 million for the
Infertility Prevention Program. In order to prevent
infertility as a consequence of chlamydial infec-
tion, the CDC recommended testing all women
with evidence of mucopurulent cervitis and all
women aged < 20 years of age. Testing was also
suggested for: (1) women aged 20–23 years who
had not consistently used barrier contraception, or
who had a new sexual partner, or more than one
sexual partner, during the previous 90 days; and
(2) women aged > 24 years who had not consis-
tently used barrier contraception, or had a new
sexual partner, or more than one sexual partner,
during the previous 90 days.
In a study performed in Baltimore [15], univer-
sal screening was compared to selective screening
(both by age and according to CDC criteria). Age-
based screening provided the greatest cost-effect-
iveness, with a prevalence of chlamydial infection
of 6.6%. The authors of the Baltimore study also
suggested that universal screening should be-
come the elective strategy if the prevalence of
infection is 6.6–10.2%, and that no screening
modality would be cost-effective with a preval-
ence of < 1.1%.
Considering the high prevalence of C. tracho-
matis infection in European countries, and the far-
reaching consequences of the disease, medical
societies and health authorities should define
guidelines and a European-wide screening policy.
Although there are clearly difficulties related to
the structure and economics of individual na-
tional healthcare systems, the development of a
comprehensive screening policy will, in time,
prove cost-effective, as it will decrease the signi-
ficant costs involved in treating the sequelae of
the infection. Attention should be given to both
primary and secondary prevention. Primary-care
physicians should be involved and educated to
contribute to this initiative [16].
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